Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer

BACKGROUND: Bevacizumab (Bev) plus platinum‐based chemotherapy is a standard first‐line treatment option for advanced non‐squamous non‐small cell lung cancer (NS‐NSCLC). We evaluated the efficacy and safety of continuing Bev in Chinese patients with advanced NS‐NSCLC progression after first‐line tre...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thorac Cancer
Huvudupphovsmän: Xing, Puyuan, Mu, Yuxin, Wang, Yan, Hao, Xuezhi, Zhu, Yixiang, Hu, Xingsheng, Wang, Hongyu, Liu, Peng, Lin, Lin, Wang, Zhijie, Li, Junling
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons Australia, Ltd 2018
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275823/
https://ncbi.nlm.nih.gov/pubmed/30324773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12886
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk